表阿霉素联奥沙利铂、卡培他滨(EOX)一线治疗晚期胃癌的临床研究分析演示幻灯片.pptVIP

表阿霉素联奥沙利铂、卡培他滨(EOX) 一线治疗晚期胃癌的临床研究分析; 背景 资料与方法 结果与讨论 结论 ;; Chemotheray VS BSC;combination vs single agent;Drug combinations;ECF (epirubicin, cisplatin, infusional 5-FU) is widely used particularly in Europe on the basis of the results of two randomized phase 3 trials and a recent meta-analysis ; ECF vs FAMTX;Waters JS, et al, Br J Cancer 1999;2. ECF vs MCF;Sumpter et al. confirmed : (EOX) epirubicin (50mg/m2, day1) oxaliplatin (130mg/m2, day1) capecitabine (500-625 mg/m2 bid. day 1-14 ) overall response rate: 48% grade 3 /4 netropenia: 40% ; 基于以上结果，我们开展了一项2期临床研究，采用EO